{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:18:16Z","timestamp":1788459496662,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s11102-026-01721-6","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T17:11:19Z","timestamp":1782925879000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The effect of hypoprolactinemia on cardiometabolic effects of rosuvastatin in men: A matched Cohort Pilot Study"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5454-2620","authenticated-orcid":false,"given":"Robert","family":"Krysiak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Kowalcze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Witold","family":"Szkr\u00f3bka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Zaami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogus\u0142aw","family":"Okopie\u0144","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"issue":"6","key":"1721_CR1","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41574-019-0194-6","volume":"15","author":"V Bernard","year":"2019","unstructured":"Bernard V, Young J, Binart N (2019) Prolactin - a pleiotropic factor in health and disease. Nat Rev Endocrinol 15(6):356\u2013365. https:\/\/doi.org\/10.1038\/s41574-019-0194-6","journal-title":"Nat Rev Endocrinol"},{"issue":"6","key":"1721_CR2","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s11154-024-09895-9","volume":"25","author":"G Corona","year":"2024","unstructured":"Corona G, Rastrelli G, Sparano C, Vignozzi L, Maggi M (2024) Acquired hypoprolactinemia in men, possible phenotype. Rev Endocr Metab Disord 25(6):1109\u201319. https:\/\/doi.org\/10.1007\/s11154-024-09895-9","journal-title":"Rev Endocr Metab Disord"},{"issue":"6","key":"1721_CR3","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s11154-024-09892-y","volume":"25","author":"V Munro","year":"2024","unstructured":"Munro V, Wilkinson M, Imran SA (2024) Neuropsychological complications of hypoprolactinemia. Rev Endocr Metab Disord 25(6):1121\u20136. https:\/\/doi.org\/10.1007\/s11154-024-09892-y","journal-title":"Rev Endocr Metab Disord"},{"issue":"6","key":"1721_CR4","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1007\/s11154-024-09890-0","volume":"25","author":"TS Han","year":"2024","unstructured":"Han TS, Antonio L, Bartfai G, O\u2019Neill TW, Punab M, Rastrelli G et al (2024) Evidence-based definition of hypoprolactinemia in European men aged 40\u201386 years: the European male ageing study. Rev Endocr Metab Disord 25(6):1097\u2013107. https:\/\/doi.org\/10.1007\/s11154-024-09890-0","journal-title":"Rev Endocr Metab Disord"},{"key":"1721_CR5","doi-asserted-by":"publisher","unstructured":"Krysiak R, Kowalcze K, Szkrobka W, Okopien B (2024) Increased Cardiometabolic Risk in Men with Hypoprolactinemia: A Pilot Study. Biomolecules 14(10). https:\/\/doi.org\/10.3390\/biom14101335","DOI":"10.3390\/biom14101335"},{"issue":"5","key":"1721_CR6","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1111\/j.1743-6109.2008.01206.x","volume":"6","author":"G Corona","year":"2009","unstructured":"Corona G, Mannucci E, Jannini EA, Lotti F, Ricca V, Monami M et al (2009) Hypoprolactinemia: a new clinical syndrome in patients with sexual dysfunction. J Sex Med 6(5):1457\u201366. https:\/\/doi.org\/10.1111\/j.1743-6109.2008.01206.x","journal-title":"J Sex Med"},{"issue":"6","key":"1721_CR7","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/j.jhep.2018.01.035","volume":"68","author":"P Zhang","year":"2018","unstructured":"Zhang P, Ge Z, Wang H, Feng W, Sun X, Chu X et al (2018) Prolactin improves hepatic steatosis via CD36 pathway. J Hepatol 68(6):1247\u201355. https:\/\/doi.org\/10.1016\/j.jhep.2018.01.035","journal-title":"J Hepatol"},{"issue":"1","key":"1721_CR8","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s12020-022-03145-1","volume":"78","author":"R Krysiak","year":"2022","unstructured":"Krysiak R, Kowalcze K, Okopien B (2022) Cardiometabolic profile of young women with hypoprolactinemia. Endocrine 78(1):135\u201341. https:\/\/doi.org\/10.1007\/s12020-022-03145-1","journal-title":"Endocrine"},{"issue":"12","key":"1721_CR9","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1007\/s40618-023-02101-8","volume":"46","author":"E Maseroli","year":"2023","unstructured":"Maseroli E, Verde N, Cipriani S, Rastrelli G, Alfaroli C, Ravelli SA et al (2023) Low prolactin level identifies hypoactive sexual desire disorder women with a reduced inhibition profile. J Endocrinol Invest 46(12):2481\u201392. https:\/\/doi.org\/10.1007\/s40618-023-02101-8","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"1721_CR10","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1093\/ejendo\/lvaf101","volume":"192","author":"TS Han","year":"2025","unstructured":"Han TS, Hannemann A, Arffman R, Friedrich N, Ittermann T, Wilkening R et al (2025) The relationship between hypoprolactinemia and cardiometabolic health in women. Eur J Endocrinol 192(5):662\u2013670. https:\/\/doi.org\/10.1093\/ejendo\/lvaf101","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"1721_CR11","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s12020-019-02170-x","volume":"67","author":"AJ Ponce","year":"2020","unstructured":"Ponce AJ, Galvan-Salas T, Lerma-Alvarado RM, Ruiz-Herrera X, Hernandez-Cortes T, Valencia-Jimenez R et al (2020) Low prolactin levels are associated with visceral adipocyte hypertrophy and insulin resistance in humans. Endocrine 67(2):331\u201343. https:\/\/doi.org\/10.1007\/s12020-019-02170-x","journal-title":"Endocrine"},{"issue":"1","key":"1721_CR12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1210\/en.2016-1444","volume":"158","author":"X Ruiz-Herrera","year":"2017","unstructured":"Ruiz-Herrera X, de Los Rios EA, Diaz JM, Lerma-Alvarado RM, Martinez de la Escalera L, Lopez-Barrera F et al (2017) Prolactin promotes adipose tissue fitness and insulin sensitivity in obese males. Endocrinology 158(1):56\u201368. https:\/\/doi.org\/10.1210\/en.2016-1444","journal-title":"Endocrinology"},{"issue":"5\u20136","key":"1721_CR13","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1159\/000527333","volume":"147","author":"R Krysiak","year":"2022","unstructured":"Krysiak R, Kowalcze K, Okopien B (2022) Cabergoline-induced hypoprolactinemia may attenuate cardiometabolic effects of atorvastatin: A Pilot Study. Cardiology 147(5\u20136):497\u2013506. https:\/\/doi.org\/10.1159\/000527333","journal-title":"Cardiology"},{"issue":"10","key":"1721_CR14","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1007\/s40618-025-02645-x","volume":"48","author":"R Krysiak","year":"2025","unstructured":"Krysiak R, Kowalcze K, Cucinella G, Gullo G, Zaami S, Ott J et al (2025) The impact of hypoprolactinemia on cardiometabolic effects of metformin in young women: a pilot prospective cohort study. J Endocrinol Invest. 48(10):2369\u201379. https:\/\/doi.org\/10.1007\/s40618-025-02645-x","journal-title":"J Endocrinol Invest."},{"issue":"5","key":"1721_CR15","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s12325-009-0025-6","volume":"26","author":"G Fabbri","year":"2009","unstructured":"Fabbri G, Maggioni AP (2009) Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us? Adv Ther 26(5):469\u201387. https:\/\/doi.org\/10.1007\/s12325-009-0025-6","journal-title":"Adv Ther"},{"issue":"3","key":"1721_CR16","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1177\/1074248408318628","volume":"13","author":"MS Kostapanos","year":"2008","unstructured":"Kostapanos MS, Milionis HJ, Elisaf MS (2008) An overview of the extra-lipid effects of rosuvastatin. J Cardiovasc Pharmacol Ther 13(3):157\u201374. https:\/\/doi.org\/10.1177\/1074248408318628","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"6","key":"1721_CR17","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s11154-024-09909-6","volume":"25","author":"AG Ioachimescu","year":"2024","unstructured":"Ioachimescu AG, Kelestimur F (2024) Drug induced hypoprolactinemia. Rev Endocr Metab Disord 25(6):1003\u201311. https:\/\/doi.org\/10.1007\/s11154-024-09909-6","journal-title":"Rev Endocr Metab Disord"},{"key":"1721_CR18","unstructured":"(2009) Food and Drug Administration. Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Effect Reporting to IRBs\u2013Improving Human Subject Protection"},{"key":"1721_CR19","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/B978-0-444-59602-4.00013-7","volume":"124","author":"JA Romijn","year":"2014","unstructured":"Romijn JA (2014) Hyperprolactinemia and prolactinoma. Handb Clin Neurol 124:185\u2013195. https:\/\/doi.org\/10.1016\/B978-0-444-59602-4.00013-7","journal-title":"Handb Clin Neurol"},{"issue":"Suppl A","key":"1721_CR20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1093\/eurheartj\/16.suppl_a.21","volume":"16","author":"AR Folsom","year":"1995","unstructured":"Folsom AR (1995) Epidemiology of fibrinogen. Eur Heart J 16(Suppl A):21\u20133. https:\/\/doi.org\/10.1093\/eurheartj\/16.suppl_a.21","journal-title":"Eur Heart J"},{"key":"1721_CR21","doi-asserted-by":"publisher","first-page":"176338","DOI":"10.1016\/j.ejphar.2024.176338","volume":"966","author":"A Attiq","year":"2024","unstructured":"Attiq A, Afzal S, Ahmad W, Kandeel M (2024) Hegemony of inflammation in atherosclerosis and coronary artery disease. Eur J Pharmacol 966:176338. https:\/\/doi.org\/10.1016\/j.ejphar.2024.176338","journal-title":"Eur J Pharmacol"},{"key":"1721_CR22","doi-asserted-by":"publisher","unstructured":"Jakubowski H, Witucki L (2025) Homocysteine Metabolites, Endothelial Dysfunction, and Cardiovascular Disease. Int J Mol Sci 26(2). https:\/\/doi.org\/10.3390\/ijms26020746","DOI":"10.3390\/ijms26020746"},{"issue":"1","key":"1721_CR23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jjcc.2020.12.013","volume":"78","author":"Y Saito","year":"2021","unstructured":"Saito Y, Tanaka A, Node K, Kobayashi Y (2021) Uric acid and cardiovascular disease: A clinical review. J Cardiol 78(1):51\u20137. https:\/\/doi.org\/10.1016\/j.jjcc.2020.12.013","journal-title":"J Cardiol"},{"issue":"1","key":"1721_CR24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1191\/1358863x02vm412ra","volume":"7","author":"JP Garg","year":"2002","unstructured":"Garg JP, Bakris GL (2002) Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med 7(1):35\u201343. https:\/\/doi.org\/10.1191\/1358863x02vm412ra","journal-title":"Vasc Med"},{"issue":"9","key":"1721_CR25","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.amjmed.2005.05.018","volume":"118","author":"PC Deedwania","year":"2005","unstructured":"Deedwania PC, Fonseca VA (2005) Diabetes, prediabetes, and cardiovascular risk: shifting the paradigm. Am J Med 118(9):939\u2013947. https:\/\/doi.org\/10.1016\/j.amjmed.2005.05.018","journal-title":"Am J Med"},{"issue":"2","key":"1721_CR26","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1080\/17446651.2018.1434412","volume":"13","author":"RS Auriemma","year":"2018","unstructured":"Auriemma RS, De Alcubierre D, Pirchio R, Pivonello R, Colao A (2018) The effects of hyperprolactinemia and its control on metabolic diseases. Expert Rev Endocrinol Metab 13(2):99\u2013106. https:\/\/doi.org\/10.1080\/17446651.2018.1434412","journal-title":"Expert Rev Endocrinol Metab"},{"key":"1721_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1159\/000486000","volume":"49","author":"M Andersen","year":"2018","unstructured":"Andersen M, Glintborg D (2018) Metabolic Syndrome in Hyperprolactinemia. Front Horm Res 49:29\u201347. https:\/\/doi.org\/10.1159\/000486000","journal-title":"Front Horm Res"},{"issue":"6","key":"1721_CR28","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1007\/s11154-024-09916-7","volume":"25","author":"J Krogh","year":"2024","unstructured":"Krogh J (2024) The homeo-FIT-prolactin hypothesis: the role of prolactin in metabolic homeostasis - association or causality? Rev Endocr Metab Disord 25(6):1077\u201386. https:\/\/doi.org\/10.1007\/s11154-024-09916-7","journal-title":"Rev Endocr Metab Disord"},{"issue":"3","key":"1721_CR29","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/npr2.12190","volume":"41","author":"M Tasaki","year":"2021","unstructured":"Tasaki M, Yasui-Furukori N, Yokoyama S, Shinozaki M, Sugawara N, Shimoda K (2021) Hypoprolactinemia and hyperprolactinemia in male schizophrenia patients treated with aripiprazole and risperidone and their relationships with testosterone levels. Neuropsychopharmacol Rep 41(3):379\u201384. https:\/\/doi.org\/10.1002\/npr2.12190","journal-title":"Neuropsychopharmacol Rep"},{"issue":"1","key":"1721_CR30","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s12020-012-9857-y","volume":"44","author":"SS Inancli","year":"2013","unstructured":"Inancli SS, Usluogullari A, Ustu Y, Caner S, Tam AA, Ersoy R et al (2013) Effect of cabergoline on insulin sensitivity, inflammation, and carotid intima media thickness in patients with prolactinoma. Endocrine 44(1):193\u20139. https:\/\/doi.org\/10.1007\/s12020-012-9857-y","journal-title":"Endocrine"},{"issue":"6","key":"1721_CR31","doi-asserted-by":"publisher","first-page":"440","DOI":"10.5152\/AnatolJCardiol.2015.6416","volume":"16","author":"BA Dogan","year":"2016","unstructured":"Dogan BA, Arduc A, Tuna MM, Nasiroglu NI, Isik S, Berker D et al (2016) Evaluation of atherosclerosis after cessation of cabergoline therapy in patients with prolactinoma. Anatol J Cardiol 16(6):440\u20137. https:\/\/doi.org\/10.5152\/AnatolJCardiol.2015.6416","journal-title":"Anatol J Cardiol"},{"issue":"9\u201310","key":"1721_CR32","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2298\/MPNS1410339K","volume":"67","author":"S Kojic Damjanov","year":"2014","unstructured":"Kojic Damjanov S, Deric M, Eremic KN (2014) Glycated hemoglobin A1c as a modern biochemical marker of glucose regulation. Med Pregl 67(9\u201310):339\u2013344","journal-title":"Med Pregl"},{"key":"1721_CR33","doi-asserted-by":"publisher","first-page":"1239335","DOI":"10.3389\/fendo.2023.1239335","volume":"14","author":"M Laakso","year":"2023","unstructured":"Laakso M, Fernandes Silva L (2023) Statins and risk of type 2 diabetes: mechanism and clinical implications. Front Endocrinol (Lausanne) 14:1239335. https:\/\/doi.org\/10.3389\/fendo.2023.1239335","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"1721_CR34","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s40119-022-00261-x","volume":"11","author":"V Fernandez-Alvarez","year":"2022","unstructured":"Fernandez-Alvarez V, Linares Sanchez M, Lopez Alvarez F, Suarez Nieto C, Makitie AA, Olsen KD et al (2022) Evaluation of intima-media thickness and arterial stiffness as early ultrasound biomarkers of carotid artery atherosclerosis. Cardiol Ther. 11(2):231\u201347. https:\/\/doi.org\/10.1007\/s40119-022-00261-x","journal-title":"Cardiol Ther."},{"issue":"7","key":"1721_CR35","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1161\/CIRCULATIONAHA.120.046361","volume":"142","author":"P Willeit","year":"2020","unstructured":"Willeit P, Tschiderer L, Allara E, Reuber K, Seekircher L, Gao L et al (2020) Carotid intima-media thickness progression as surrogate marker for cardiovascular risk: meta-analysis of 119 clinical trials involving 100 667 patients. Circulation 142(7):621\u201342. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.046361","journal-title":"Circulation"},{"issue":"1","key":"1721_CR36","doi-asserted-by":"publisher","first-page":"108","DOI":"10.5551\/jat.14001","volume":"20","author":"Y Huang","year":"2013","unstructured":"Huang Y, Li W, Dong L, Li R, Wu Y (2013) Effect of statin therapy on the progression of common carotid artery intima-media thickness: an updated systematic review and meta-analysis of randomized controlled trials. J Atheroscler Thromb 20(1):108\u201321. https:\/\/doi.org\/10.5551\/jat.14001","journal-title":"J Atheroscler Thromb"},{"issue":"4","key":"1721_CR37","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.endien.2021.03.004","volume":"69","author":"R Krysiak","year":"2022","unstructured":"Krysiak R, Kowalcze K, Okopien B (2022) Sexual function and depressive symptoms in men with hypoprolactinaemia secondary to overtreatment of prolactin excess: A pilot study. Endocrinol Diabetes Nutr (Engl Ed) 69(4):279\u2013288. https:\/\/doi.org\/10.1016\/j.endien.2021.03.004","journal-title":"Endocrinol Diabetes Nutr (Engl Ed)"},{"key":"1721_CR38","doi-asserted-by":"publisher","unstructured":"Krysiak R, Kowalcze K, Okopien B. Sexual function and depressive symptoms in young women with hypoprolactinaemia. Clin Endocrinol (Oxf). 2020;93(4):482\u20138. Epub 20200726. https:\/\/doi.org\/10.1111\/cen.14283. PubMed PMID: 32654174.","DOI":"10.1111\/cen.14283"},{"issue":"9","key":"1721_CR39","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1016\/j.jsxm.2018.06.012","volume":"15","author":"G Corona","year":"2018","unstructured":"Corona G, Rastrelli G, Di Pasquale G, Sforza A, Mannucci E, Maggi M (2018) Endogenous testosterone levels and cardiovascular risk: meta-analysis of observational studies. J Sex Med 15(9):1260\u201371. https:\/\/doi.org\/10.1016\/j.jsxm.2018.06.012","journal-title":"J Sex Med"},{"issue":"2","key":"1721_CR40","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s12020-024-04019-4","volume":"87","author":"GA Vasquez-Tirado","year":"2025","unstructured":"Vasquez-Tirado GA, Guarniz-Salavarria JD, Quispe-Castaneda CV, Contreras-Cabrera JM, Cuadra-Campos MDC, Meregildo-Rodriguez ED et al (2025) Testosterone levels and risk of newly diagnosed type 2 diabetes mellitus in adult men: systematic review and meta-analysis. Endocrine 87(2):362\u201377. https:\/\/doi.org\/10.1007\/s12020-024-04019-4","journal-title":"Endocrine"},{"issue":"7","key":"1721_CR41","doi-asserted-by":"publisher","first-page":"e100409","DOI":"10.1371\/journal.pone.0100409","volume":"9","author":"JS Brand","year":"2014","unstructured":"Brand JS, Rovers MM, Yeap BB, Schneider HJ, Tuomainen TP, Haring R et al (2014) Testosterone, sex hormone-binding globulin and the metabolic syndrome in men: an individual participant data meta-analysis of observational studies. PLoS One 9(7):e100409. https:\/\/doi.org\/10.1371\/journal.pone.0100409","journal-title":"PLoS One"},{"issue":"2","key":"1721_CR42","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1590\/S1677-5538.IBJU.2023.0578","volume":"50","author":"FPA Glina","year":"2024","unstructured":"Glina FPA, Lopes L, Barros EAC, Biselli B, Glina S (2024) Do statins decrease testosterone in men? Systematic review and meta-analysis. Int Braz J Urol 50(2):119\u201335. https:\/\/doi.org\/10.1590\/S1677-5538.IBJU.2023.0578","journal-title":"Int Braz J Urol"},{"key":"1721_CR43","doi-asserted-by":"publisher","first-page":"988266","DOI":"10.3389\/fcvm.2022.988266","volume":"9","author":"W Li","year":"2022","unstructured":"Li W, Jin K, Luo J, Xu W, Wu Y, Zhou J et al (2022) NF-kappaB and its crosstalk with endoplasmic reticulum stress in atherosclerosis. Front Cardiovasc Med 9:988266. https:\/\/doi.org\/10.3389\/fcvm.2022.988266","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"1721_CR44","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13075-017-1290-4","volume":"19","author":"MG Ledesma-Colunga","year":"2017","unstructured":"Ledesma-Colunga MG, Adan N, Ortiz G, Solis-Gutierrez M, Lopez-Barrera F, Martinez de la Escalera G et al (2017) Prolactin blocks the expression of receptor activator of nuclear factor kappaB ligand and reduces osteoclastogenesis and bone loss in murine inflammatory arthritis. Arthritis Res Ther 19(1):93. https:\/\/doi.org\/10.1186\/s13075-017-1290-4","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"1721_CR45","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1093\/molehr\/gaz038","volume":"25","author":"A Olmos-Ortiz","year":"2019","unstructured":"Olmos-Ortiz A, Deciga-Garcia M, Preciado-Martinez E, Bermejo-Martinez L, Flores-Espinosa P, Mancilla-Herrera I et al (2019) Prolactin decreases LPS-induced inflammatory cytokines by inhibiting TLR-4\/NFkappaB signaling in the human placenta. Mol Hum Reprod 25(10):660\u2013667. https:\/\/doi.org\/10.1093\/molehr\/gaz038","journal-title":"Mol Hum Reprod"},{"key":"1721_CR46","doi-asserted-by":"publisher","unstructured":"Khan S, Huda B, Bhurka F, Patnaik R, Banerjee Y (2025) Molecular and Immunomodulatory Mechanisms of Statins in Inflammation and Cancer Therapeutics with Emphasis on the NF-kappaB, NLRP3 Inflammasome, and Cytokine Regulatory Axes. Int J Mol Sci 26(17). https:\/\/doi.org\/10.3390\/ijms26178429","DOI":"10.3390\/ijms26178429"},{"issue":"3","key":"1721_CR47","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1677\/joe.0.1520447","volume":"152","author":"JH Shand","year":"1997","unstructured":"Shand JH, West DW, Flint DJ (1997) Effects of growth hormone on cholesterol metabolism in the lactating rat mammary gland. J Endocrinol 152(3):447\u2013454. https:\/\/doi.org\/10.1677\/joe.0.1520447","journal-title":"J Endocrinol"},{"issue":"1S","key":"1721_CR48","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1016\/j.chest.2020.03.014","volume":"158","author":"X Wang","year":"2020","unstructured":"Wang X, Kattan MW (2020) Cohort studies: design, analysis, and reporting. Chest 158(1S):S72\u2013S78. https:\/\/doi.org\/10.1016\/j.chest.2020.03.014","journal-title":"Chest"}],"updated-by":[{"DOI":"10.1007\/s11102-026-01744-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000}}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-026-01721-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-026-01721-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-026-01721-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:42:13Z","timestamp":1788457333000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-026-01721-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1721"],"URL":"https:\/\/doi.org\/10.1007\/s11102-026-01721-6","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"22 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11102-026-01744-z","URL":"https:\/\/doi.org\/10.1007\/s11102-026-01744-z","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by\u00a0the institutional committee on human research (the Bioethical Committee of the Medical University of Silesia, Katowice, Poland\u2014KNW\/0022\/KB\/207\/17).","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was reviewed and approved by the Bioethical Committee of the Medical University of Silesia.","order":2,"name":"Ethics","label":"Institutional approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The participants provided written informed consent after risks and benefits of the study had been explained.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No competing financial interests exist. The authors report no financial, personal, political, intellectual or religious conflicts of interest. The authors alone are responsible for the content and writing of the paper.","order":5,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"113"}}